source
- Biopharma optimism climbs after FDA commissioner Makary's exit, survey findsEndpoints Signal released its Q3 Biopharma Sentiment Index, showing the highest level of industry optimism in years, according to a survey of 569 insiders. The index’s regulatory score rose sharpl…
- Gubra aims to expand beyond obesity drugs, targets first portfolio partner this yearCopenhagen‑based biotech Gubra is currently known for its obesity drug candidates, but the company says its long‑term growth will depend on a broader pipeline beyond metabolism. The firm’s existin…